Helicobacter Hepaticus-induced Colitis in Interleukin-10-deficient Mice: Cytokine Requirements for the Induction and Maintenance of Intestinal Inflammation
Overview
Affiliations
We have previously shown that specific-pathogen-free interleukin-10 (IL-10)-deficient (IL-10 KO) mice reconstituted with Helicobacter hepaticus develop severe colitis associated with a Th1-type cytokine response. In the present study, we formally demonstrate that IL-12 is crucial for disease induction, because mice deficient for both IL-10 and IL-12 p40 show no intestinal pathology following H. hepaticus infection. By using monoclonal antibodies (MAbs) to IL-12, gamma interferon (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha), we have further analyzed the role of these cytokines in the maintenance of the Th1 response and inflammation in IL-10 KO mice with established H. hepaticus-induced colitis. Treatment of infected colitic IL-10 KO mice with anti-IL-12 p40 resulted in markedly reduced intestinal inflammation, colonic IFN-gamma, TNF-alpha, and inducible nitric oxide synthase (iNOS) mRNA levels, and H. hepaticus-specific IFN-gamma secretion by mesenteric lymph node (MLN) cells compared to the findings in control MAb-treated mice. Moreover, the diminished pathology was associated with decreased numbers of colonic CD3(+) T cells and significantly reduced frequencies of Helicobacter-reactive CD4(+) Th1 cells in MLN. In contrast, anti-IFN-gamma and/or anti-TNF-alpha had no effect on intestinal inflammation in IL-10 KO mice with established colitis. Using IL-10/IFN-gamma double-deficient mice, we further show that IFN-gamma is not required for the development of colitis following H. hepaticus infection. MLN cells from infected IL-10/IFN-gamma KO animals secreted elevated amounts of IL-12 and TNF-alpha following bacterial antigen stimulation, indicating alternative pathways of disease induction. Taken together, our results demonstrate a crucial role for IL-12 in both inducing and sustaining intestinal inflammation through recruitment and maintenance of a pool of pathogenic Th1 cells.
Langgartner D, Weiss A, Amoroso M, Sterrett J, Lowry C, Reber S Front Neurosci. 2025; 18:1488603.
PMID: 39944521 PMC: 11813930. DOI: 10.3389/fnins.2024.1488603.
Carlini V, Noonan D, Abdalalem E, Goletti D, Sansone C, Calabrone L Front Immunol. 2023; 14:1161067.
PMID: 37359549 PMC: 10287165. DOI: 10.3389/fimmu.2023.1161067.
Gut microbiota modulates bleomycin-induced acute lung injury response in mice.
Yoon Y, Hrusch C, Fei N, Barron G, Mills K, Hollinger M Respir Res. 2022; 23(1):337.
PMID: 36496380 PMC: 9741526. DOI: 10.1186/s12931-022-02264-7.
Barron M, Sovacool K, Abernathy-Close L, Vendrov K, Standke A, Bergin I mBio. 2022; 13(4):e0190422.
PMID: 35900107 PMC: 9426610. DOI: 10.1128/mbio.01904-22.
Overacre-Delgoffe A, Bumgarner H, Cillo A, Burr A, Tometich J, Bhattacharjee A Immunity. 2021; 54(12):2812-2824.e4.
PMID: 34861182 PMC: 8865366. DOI: 10.1016/j.immuni.2021.11.003.